Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2022; 21(02): 142-147
DOI: 10.1055/s-0042-1750336
Original Article

Planar 99mTc-PSMA Imaging of Prostate Cancer in a Low-Resource Setting: A Series Report

A.T. Orunmuyi
1   Department of Nuclear Medicine, College of Medicine, University of Ibadan and University College Hospital, Ibadan, Nigeria
,
A.A. Oladeji
2   Radiation Oncology Department, College of Medicine, University of Ibadan and University College Hospital, Ibadan, Nigeria
,
E.U. Azodoh
3   Chivar Clinics and Urology Centre, FCT Abuja, Nigeria
,
O.A. Omisanjo
4   Department of Surgery, Urology Division, Lagos State University College of Medicine and Lagos State University Teaching Hospital, Ikeja, Nigeria
,
E.O. Olapade-Olaopa
5   Department of Surgery, Urology Division, College of Medicine, University of Ibadan and University College Hospital, Ibadan, Nigeria
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Objective Technetium-99m labeled prostate-specific membrane antigen (PSMA) single-photon emission computed tomography/computed tomography (SPECT/CT) is a suitable alternative to prostate-specific membrane antigen-positron emission tomography (PSMA-PET) imaging. However, the availability of SPECT/CT in many developing countries is limited.

Materials and Methods To evaluate the utility of planar 99mTc-PSMA in the absence of SPECT/CT, we compared planar 99mTc-PSMA and routine bone scan imaging in low-, intermediate-, and high-risk prostate cancer in five patients with histologically confirmed prostate cancer who had both scans within a period of less than 4 days. The mean age of patients was 66.8 ± 5.24, and the median prostate-specific antigen level was 175 ng/mL (range: 0–778 ng/mL).

Results Planar 99mTc-PSMA scan provided no additional benefit over bone scans in the low-risk prostate cancer cases. In the cases with intermediate-risk prostate cancers, planar 99mTc-PSMA indicated complete and partial response to treatment in oligometastatic and widespread metastatic disease, respectively. In one patient with high-risk prostate cancer, planar 99mTc-PSMA detected additional skeletal lesions that were not seen on bone scan.

Conclusion In the absence of SPECT/CT, planar 99mTc-PSMA was useful for confirming extent of disease in treated intermediate- and high-risk prostate cancer. It showed little value in low-risk prostate cancer, especially when bone scan is normal. It was particularly useful for treatment response assessment in oligometastatic disease, and its utility should be further explored.

Keywords

planar 99mTc HYNIC PSMA - bone scan - equivocal scans - SPECT

Authors' Contribution

OAT was involved in conceptualization, design, definition of intellectual content, clinical studies, data acquisition, data analysis, statistical analysis, manuscript preparation, and manuscript review. AAO was involved in literature search, clinical studies, data acquisition, data analysis, manuscript editing, and review. EUA was involved in literature search, clinical studies, data acquisition, manuscript editing, and review. OAO was involved in designing, clinical studies, data acquisition, data analysis, manuscript preparation, and review. EOO was involved in designing, clinical studies, data acquisition, manuscript preparation, editing, and review. OAT has provided guarantee.


Sources of Support

None.




Publication History

Article published online:
28 June 2022

© 2022. World Association of Radiopharmaceutical and Molecular Therapy (WARMTH). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Hofman MS, Lawrentschuk N, Francis RJ. et al; proPSMA Study Group Collaborators. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020; 395 (10231): 1208-1216
    CrossrefPubMedSearch in Google Scholar
  • 2 Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific membrane antigen PET: Clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics 2018; 38 (01) 200-217
    CrossrefPubMedSearch in Google Scholar
  • 3 Lawal IO, Ankrah AO, Mokgoro NP, Vorster M, Maes A, Sathekge MM. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: a comparative analysis with Ga-68 PSMA PET/CT. Prostate 2017; 77 (11) 1205-1212
    CrossrefPubMedSearch in Google Scholar
  • 4 Orunmuyi AT, Lawal IO, Omofuma OO, Taiwo OJ, Sathekge MM. Underutilisation of nuclear medicine scans at a regional hospital in Nigeria: need for implementation research. Ecancermedicalscience 2020; 14: 1093
    CrossrefPubMedSearch in Google Scholar
  • 5 Rathke H, Afshar-Oromieh A, Giesel FL. et al. Intraindividual comparison of 99mtc-methylene diphosphonate and prostate-specific membrane antigen ligand 99mTc-MIP-1427 in patients with osseous metastasized prostate cancer. J Nucl Med 2018; 59 (09) 1373-1379
    CrossrefPubMedSearch in Google Scholar
  • 6 Schmidkonz C, Cordes M, Beck M. et al. Assessment of treatment response by 99mTc-MIP-1404 SPECT/CT: a pilot study in patients with metastatic prostate cancer. Clin Nucl Med 2018; 43 (08) e250-e258
    CrossrefPubMedSearch in Google Scholar
  • 7 Hillier SM, Maresca KP, Lu G. et al. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med 2013; 54 (08) 1369-1376
    CrossrefPubMedSearch in Google Scholar
  • 8 Schmidkonz C, Goetz TI, Kuwert T. et al. PSMA SPECT/CT with 99mTc-MIP-1404 in biochemical recurrence of prostate cancer: predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels. Ann Nucl Med 2019; 33 (12) 891-898
    CrossrefPubMedSearch in Google Scholar
  • 9 Dondi M, Kashyap R, Paez D. et al. Trends in nuclear medicine in developing countries. J Nucl Med 2011; 52 (Suppl. 02) 16S-23S
    CrossrefPubMedSearch in Google Scholar
  • 10 Al-Tamimi A, Tan AE, Kwong SY, Sam CC, Chong A, Tan CH. False-negative bone scan and choline pet/ct study in a case of prostate cancer: the pitfall of the small cell prostate carcinoma variant. World J Nucl Med 2012; 11 (02) 75-78
    Thieme ConnectPubMedSearch in Google Scholar
  • 11 Scher HI, Solo K, Valant J, Todd MB, Mehra M. Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model. PLoS One 2015; 10 (10) e0139440
    CrossrefPubMedSearch in Google Scholar
  • 12 Ferro-Flores G, Luna-Gutiérrez M, Ocampo-García B. et al. Clinical translation of a PSMA inhibitor for 99mTc-based SPECT. Nucl Med Biol 2017; 48: 36-44
    CrossrefPubMedSearch in Google Scholar
  • 13 Petersen LJ, Johansen MN, Strandberg J, Stenholt L, Zacho HD. Reporting and handling of equivocal imaging findings in diagnostic studies of bone metastasis in prostate cancer. Acta Radiol 2020; 61 (08) 1096-1104
    CrossrefPubMedSearch in Google Scholar